Genetically modified plants for food use and human health an update

March 1, 2018

The Society periodically issues updates on reports (recent examples include updates on bovine spongiform encephalopathies and stem cells) and the following update, which is based on research published in the last three years, specifically addresses human health aspects of genetically modified foods and the principle of substantial equivalence. The statement has been prepared by a working group chaired by Professor Jim Smith FRS (Wellcome CRC Institute, Cambridge).

Spotlight

Adelphi Group

The Adelphi Group provides a wide range of strategic support services and consulting for global pharmaceutical clients. Adelphi is dedicated to the healthcare sector, providing services across strategic marketing, marketing and business intelligence, real-world observational research and disease-specific programmes, health and economic outcomes, market access, pricing and reimbursement, value insight, multi-channel health communications, scientific services, medical education, and strategic product

OTHER WHITEPAPERS
news image

Pioneering Cell and Gene Therapy Solutions From Discovery to the Clinic

whitePaper | April 14, 2020

Your vision is to create revolutionary cell and gene therapies to treat life threatening diseases. Bio-Techne and its family of brands is on this journey with you. As a full-solution ancillary reagent and services provider, we will stand by you, providing flexible and pioneering tools to simplify your workflow. From CAR T cells to pluripotent stem cells, let us help you get your therapy to the patients that need it

Read More
news image

Advanced Biopharmaceutical Manufacturing: An Evolution Underway

whitePaper | June 5, 2022

The past decade has seen a significant shift in the nature of the products being manufactured and sold by the innovative biopharmaceutical (biopharma) industry. The global biopharmaceutical portfolio of today reflects increased therapeutic competition, a greater prevalence of large molecule drugs, expansion in the number of personalized or targeted products, and a rise of treatments for many orphan diseases.

Read More
news image

Covid-19 Vaccine Distribution System

whitePaper | April 14, 2021

Delivering Covid-19 vaccines to 7.8 billion people is a daunting challenge that will stretch supply chains past their limits. Even if all the needed doses were ready today, vaccine manufacturers still must find solutions to deliver multiple doses of those vaccines to most people on the planet. To read more, please download this free white paper.

Read More
news image

Cell Lysate Sample Handling with Simoa Bead-Based Assays

whitePaper | November 12, 2019

This document describes a novel Quanterix lysate diluent for running lysate samples with Simoa assays diluent.

Read More
news image

Next Generation Therapies and related Life Sciences topics

whitePaper | January 16, 2022

All gene therapies insert engineered DNA/RNA into living cells to make or modify new proteins

Read More
news image

Biosimilars – commercial best practices in the age of sustainability

whitePaper | November 4, 2019

Revenues from biologics increased by 70% from 2011 to 2016. Biologics account for 20-22% of total pharmaceutical spending. IQVIA estimates US biologics spending will reach $320bn by 2023

Read More

Spotlight

Adelphi Group

The Adelphi Group provides a wide range of strategic support services and consulting for global pharmaceutical clients. Adelphi is dedicated to the healthcare sector, providing services across strategic marketing, marketing and business intelligence, real-world observational research and disease-specific programmes, health and economic outcomes, market access, pricing and reimbursement, value insight, multi-channel health communications, scientific services, medical education, and strategic product

Events